Medivation Reports Third Quarter 2009 Financial Results and Provides Corpor...(2009 2008 2009 2008 ...),Health

Date:11/4/2009

2009 2008 2009 2008 ---- ---- ---- ---- Collaboration revenue $16,341 $- $49,021 $- ------- -- ------- -- Operating expenses: Research and development 21,530 15,514 54,851 41,728 Selling, general and administrative 6,034 5,122 18,950 13,532 ------ ------ ------ ------ Total operating expenses 27,564 20,636 73,801 55,260 ------ ------ ------ ------ Loss from operations (11,223) (20,636) (24,780) (55,260) Other income (expense): Interest income 153 170 967 735 Other income (expense), net (57) 10 (154) (2) --- -- ---- -- Total other income 96 180 813 733 -- --- --- --- Loss before provision for income taxes (11,127) (20,456) (23,967) (54,527) Provision for income taxes 2,846 - 4,538 2 ----- --- ----- --- Net loss $(13,973) $(20,456) $(28,505) $(54,529) ======== ======== ======== ======== Basic and diluted net loss per share $(0.42) $(0.68) $(0.90) $(1.86) ====== ====== ====== ====== Weighted average common shares used in the calculation of basic and diluted net loss per share 33,468 30,022 31,58
'/>"/>

SOURCE Medivation, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease